Rhonda Farnum Sells 4,000 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) Stock

Theravance Biopharma, Inc. (NASDAQ:TBPH) SVP Rhonda Farnum sold 4,000 shares of the business’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $9.00, for a total value of $36,000.00. Following the completion of the sale, the senior vice president now owns 309,565 shares in the company, valued at $2,786,085. This represents a 1.28 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Rhonda Farnum also recently made the following trade(s):

• On Monday, November 11th, Rhonda Farnum sold 4,000 shares of Theravance Biopharma stock. The shares were sold at an average price of $9.00, for a total transaction of $36,000.00.

Theravance Biopharma Trading Up 3.3 %

Theravance Biopharma stock opened at $9.67 on Friday. The firm has a 50 day simple moving average of $9.45 and a 200 day simple moving average of $8.90. Theravance Biopharma, Inc. has a 1-year low of $7.44 and a 1-year high of $10.44.

Theravance Biopharma (NASDAQ:TBPH) last issued its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.16). Theravance Biopharma had a negative return on equity of 24.79% and a negative net margin of 78.18%. The company had revenue of $16.87 million during the quarter, compared to the consensus estimate of $16.11 million. During the same quarter in the prior year, the business earned ($0.17) EPS. Analysts anticipate that Theravance Biopharma, Inc. will post -1.09 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Theravance Biopharma

Several hedge funds have recently bought and sold shares of TBPH. Quantbot Technologies LP purchased a new stake in Theravance Biopharma in the 3rd quarter worth approximately $60,000. China Universal Asset Management Co. Ltd. increased its holdings in shares of Theravance Biopharma by 64.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 9,409 shares of the biopharmaceutical company’s stock worth $76,000 after purchasing an additional 3,696 shares during the period. Hsbc Holdings PLC purchased a new stake in shares of Theravance Biopharma in the second quarter worth $108,000. Ballentine Partners LLC bought a new stake in Theravance Biopharma during the third quarter valued at $104,000. Finally, XTX Topco Ltd purchased a new position in Theravance Biopharma during the second quarter worth about $129,000. Hedge funds and other institutional investors own 99.10% of the company’s stock.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.